Low bone mass in prepubertal children with Thalassemia major: Insights into the pathogenesis of low bone mass in Thalassemia

被引:0
作者
Vogiatzi, MG
Autio, KA
Schneider, R
Giardina, PJ
机构
[1] Cornell Univ, Dept Pediat, New York Presbyterian Hosp, Weill Med Coll, Ithaca, NY 14853 USA
[2] Hosp Special Surg, Dept Radiol & Imaging, New York, NY 10021 USA
关键词
bone mineral density; osteoporosis; osteopenia; bone resorption;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Low bone mass occurs frequently in the aging thalassemic population. However, limited information exists on bone mass in children with thalassemia major (TM) during their first decade of life. Study design: Spinal bone mineral density (BMD) was measured by dual-energy X-ray absorptiometry (DEXA) in 18 children (age 5.8 +/- 1.5 yr; M:F 8:10) with TM on hypertransfusion and iron chelation therapy. Serial BMD measurements were available for 11 of the 18 children. Results: Weight and height z scores were 0.81 +/- 4.2 and -0.47 +/- 1.7 respectively. At the first BMD, four (22.2%) patients presented with BMD z scores less than -2.5, seven (38.8%) had BMD z scores between -1 and -2.5, while the remaining seven (38.8%) had normal BMDs (z score above -1). The mean decline of BMD z score was -0.38/year (p = ns). BMD z scores correlated with height z scores (p = 0.039), but not with liver enzymes, serum ferritin levels, or thalassemia genotypes. Conclusions: Low bone mass is present in most children with TM despite hypertransfusion and optimal chelation, adequate growth and lack of endocrine complications.
引用
收藏
页码:1415 / 1421
页数:7
相关论文
共 29 条
[1]   THE CONTRIBUTION OF HYPOGONADISM TO THE DEVELOPMENT OF OSTEOPOROSIS IN THALASSEMIA MAJOR - NEW THERAPEUTIC APPROACHES [J].
ANAPLIOTOU, MLG ;
KASTANIAS, IT ;
PSARA, P ;
EVANGELOU, EA ;
LIPARAKI, M ;
DIMITRIOU, P .
CLINICAL ENDOCRINOLOGY, 1995, 42 (03) :279-287
[2]  
[Anonymous], 1925, Trans Am Pediatr Soc
[3]   Acquisition of optimal bane mass in childhood and adolescence [J].
Bachrach, LK .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2001, 12 (01) :22-28
[4]   DEFEROXAMINE-INDUCED BONE DYSPLASIA IN PATIENTS WITH THALASSEMIA MAJOR [J].
BRILL, PW ;
WINCHESTER, P ;
GIARDINA, PJ ;
CUNNINGHAMRUNDLES, S .
AMERICAN JOURNAL OF ROENTGENOLOGY, 1991, 156 (03) :561-565
[5]  
DELRIO LD, 1994, PEDIATR RES, V35, P362, DOI 10.1203/00006450-199403000-00018
[6]   GONADAL-FUNCTION IN PATIENTS WITH BETA-THALASSEMIA MAJOR [J].
DESANCTIS, V ;
VULLO, C ;
KATZ, M ;
WONKE, B ;
TANAS, R ;
BAGNI, B .
JOURNAL OF CLINICAL PATHOLOGY, 1988, 41 (02) :133-137
[7]  
DEVIRGILIS S, 1998, J PEDIATR, V113, P661
[8]   Longitudinal monitoring of bone mineral density in thalassemic patients. Genetic structure and osteoporosis [J].
Filosa, A ;
DiMaio, S ;
Vocca, S ;
Saviano, A ;
Esposito, G ;
Pagano, L .
ACTA PAEDIATRICA, 1997, 86 (04) :342-346
[9]  
GERTNER JM, 1979, J PEDIATR-US, V95, P210
[10]  
GIARDINA PJ, 1995, SEMIN HEMATOL, V32, P304